drugset / Trial / NCT07182526

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

NCT07182526

Phase 2 Recruiting 150 enrolled Al-Mustansiriyah University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.

Timeline

Start
2025-09-20
Primary completion
2026-05-01
Completion
2026-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quercetin Small molecule 500 mg Oral
Subject alpha-lipoic acid Small molecule 600 mg Oral
Background Metformin Small molecule 500 mg Oral